Compare
Jaguar Health, Inc. vs Prelude Therapeutics Inc vs Crescent Biopharma, Inc. vs Emmaus Life Sciences, Inc.
| Latest fiscal year | Jaguar Health, Inc. JAGX | Prelude Therapeutics Inc PRLD | Crescent Biopharma, Inc. CBIO | Emmaus Life Sciences, Inc. EMMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.51M | $12.14M | $10.84M | $12.45M |
| Revenue growth (YoY) | -1.5% | +73.4% | n/a | -25.2% |
| Gross margin | 67.2% (computed) | n/a | n/a | 93.1% |
| Operating margin | -398.8% | -861.3% | n/m | 1.9% |
| Net margin | -465.4% | -819.6% | n/m | -60.2% |
| Net income | -$53.58M | -$99.50M | -$153.94M | -$7.49M |
| EPS (Diluted) | -$22.97 | -$1.29 | n/a | -$0.12 |
| Operating cash flow | -$23.69M | -$56.30M | -$71.53M | -$11.0K |
| Free cash flow | n/a | -$56.37M | -$72.45M | -$12.0K |
| Cash & equivalents | $968.0K | $35.26M | $213.19M | $2.13M |
| Total assets | $38.32M | $141.31M | $240.29M | $21.44M |
| Total liabilities | $57.01M | $72.68M | $37.28M | $85.04M |
| Shareholders' equity | -$18.69M | $68.64M | $203.01M | -$63.61M |
| Return on year-end equity | n/a | -145.0% | -75.8% | n/a |
| Shares outstanding | n/a | n/a | 27.56M | 70.19M |
Revenue, most recent five fiscal years
| Fiscal year | Jaguar Health, Inc. | Prelude Therapeutics Inc | Crescent Biopharma, Inc. | Emmaus Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $11.51M Ended 2025-12-31 | $12.14M Ended 2025-12-31 | $10.84M Ended 2025-12-31 | $12.45M Ended 2025-12-31 |
| 1 year earlier | $11.69M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | n/a | $16.65M Ended 2024-12-31 |
| 2 years earlier | $9.76M Ended 2023-12-31 | n/a | n/a | $29.60M Ended 2023-12-31 |
| 3 years earlier | $11.96M Ended 2022-12-31 | n/a | n/a | $18.39M Ended 2022-12-31 |
| 4 years earlier | $4.33M Ended 2021-12-31 | n/a | n/a | $20.61M Ended 2021-12-31 |